Clinical Trial

Disease: Congenital Hearing Loss, (NCT06025032)

Disease info:

Congenital hearing loss refers to hearing loss that is present before a child learns to speak. Variations in the OTOF gene, which encodes the calcium-binding protein otoferlin, are responsible for 1-8% cases of congenital, nonsyndromic hearing loss and are the leading cause of auditory neuropathy spectrum disorders. Nonsyndromic hearing loss is a partial or total loss of hearing that is not associated with other signs and symptoms. This aim of this study is to use CRISPR-Cas13 technology to perform RNA base-editing of a commonly found diseasing-causing mutation (p.Q829X) in OTOF.

Source:

Ford CL, Riggs WJ, Quigley T, Keifer OP Jr, Whitton JP, Valayannopoulos V. The natural history, clinical outcomes, and genotype-phenotype relationship of otoferlin-related hearing loss: a systematic, quantitative literature review. Hum Genet. 2023 Oct;142(10):1429-1449. 

Frequency:
Congenital hearing loss affects one in 500 newborns.
Official title:
An Open-label, Multiple-cohort, Dose-finding, Investigator-initiated Trial to Evaluate the Safety, Tolerability, and Efficacy of HG205 RNA Base-Editing Therapy in Subjects With OTOF-p.Q829X Mutation-associated Hearing Loss
Who:

Contact

Name: Study Director

Phone: +86 021-25076143

Email: HG20501@huidagene.com 

Partners:

Eye & ENT Hospital of Fudan University
 

Locations:

China
Eye & ENT Hospital of Fudan University, Shanghai, China

Study start:
Nov. 30, 2023
Enrollment:
6 participants
Gene editing method:
CRISPR-Cas13
Type of edit:
RNA Base-Editing
Gene:
Otoferlin (OTOF) gene
Delivery method:
Adeno-associated virus (AAV)
Indicator
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Not yet recruiting

Description

The purpose of the study is to determine whether HG205 as CRISPR/Cas13 RNA base-editing therapy is safe and effective for the treatment of hearing loss caused by p.Q829X mutation in OTOF gene.

Last updated: Feb. 5, 2024
close
Search CRISPR Medicine